Point-Of-Care Lateral Flow Reader Delivers High-Sensitivity Measurements In 10 Seconds
|
By LabMedica International staff writers Posted on 12 Aug 2024 |
|
A customizable point-of-care (POC) lateral flow reader combines advanced imaging technology and proprietary algorithms to deliver high-sensitivity measurements in just 10 seconds.
The miniDxR lateral flow reader designed by DCN Dx (Carlsbad, CA, USA) for POC testing offers advanced imaging technology, superior sensitivity and specificity, and robust cybersecurity features. It is customizable for diverse diagnostic applications, providing reliable and accurate results in diverse POC settings. The miniDxR utilizes advanced camera-based colorimetry and fluorescence for accurate and precise color and intensity detection, vital for the most sensitive POC diagnostics. It features a modular cartridge nest that can be customized to accommodate a wide variety of lateral flow assay cassettes, ensuring compatibility with a laboratory’s specific needs.
The miniDxR boasts a user-friendly interface with a vibrant color display and simple three-button control, enabling effortless operation even in fast-paced POC environments and while using gloves. Additional options are available to adapt screen size and button controls. It offers versatile “batch” and “single test” modes to accommodate diverse testing protocols, allowing labs to analyze pre-run assays or monitor lateral flow assays in real-time at the POC. Additionally, the miniDxR safeguards sensitive data with robust encryption and adheres to rigorous international standards, including FCC, IEC 61326, IEC 61010, IEC 60601, and IEC 62304, ensuring suitability for POC use.
The miniDxR offers a variety of customization options, from software workflows and data presentation to hardware modifications and branding. Every customized miniDxR unit comes with standard features such as pre-submission materials, product and software requirements, risk analysis, cybersecurity measures, verifications, and completion of the Design History File per FDA requirements. The miniDxR is designed to excel in both sophisticated clinical labs and challenging field environments.
"From its advanced capabilities to its range of customization options, our team designed this reader with the specific needs of point-of-care testing in mind," said Pat Vaughan, Ph.D., COO of DCN Dx.
Related Links:
DCN Dx
Latest Molecular Diagnostics News
- Portable Test Differentiates Seven Mosquito-Borne Viruses at Point of Care
- Rapid Genetic Test Aims to Shorten Brain Tumor Diagnosis Time
- Long-Read Sequencing Test Identifies Genetic Causes in Inherited Muscle Disease
- Genetic Testing Program Helps Uncover Inherited Risk in Pediatric Cancer
- Genomic Test Guides Extended Endocrine Therapy in Early Breast Cancer
- Genomic Breast Cancer Study Adds Real-World Evidence Across Diverse Patient Populations
- New Oncology Assays Deliver Precise Molecular Counts with MRD-Grade Sensitivity
- Molecular Skin Test May Help Guide Treatment Selection in Atopic Dermatitis
- CSF Liquid Biopsy Could Help Distinguish Cancer from Autoimmune Brain Inflammation
- Blood Test Stratifies Prostate and Breast Cancer Risk Years Before Diagnosis
- Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis
- Mpox Analysis Reveals Substantial Suspected False Positives Associated with Contamination
- Liquid Biopsy Shows Promise for Detecting and Monitoring Malignant Nerve Sheath Tumors
- Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery
- Electronic Genome Mapping Reveals Structural Abnormalities in Hematologic Malignancies
- Rare Genetic Variant Linked to Dramatically Higher Lung Cancer Risk
Channels
Clinical Chemistry
view channel
Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke
Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more
Breath Analysis Shows Promise for Distinguishing Cancerous from Benign Lung Nodules
Lung nodules are frequently detected during imaging, but distinguishing malignant from benign findings can require invasive procedures. Some patients undergo biopsies, bronchoscopy, or surgery before learning... Read more
Hematology
view channel
New Donor Genetic Marker May Help Predict Stem Cell Transplant Success
Donor selection for hematopoietic stem cell transplantation plays a major role in relapse risk and survival for patients with blood cancers and other blood disorders. Despite advances in genotyping, uncertainty... Read more
Updated Ferritin Thresholds Improve Detection of Iron Deficiency
Iron deficiency is one of the most common health conditions worldwide, yet its nonspecific symptoms can delay diagnosis for months. Variation in testing practices and ferritin thresholds may contribute... Read more
Immunology
view channel
Blood Test Differentiates Bacterial and Viral Infections in Febrile Infants
Fever in infants younger than 3 months is treated as a medical emergency because infections can become life-threatening while the immune system is still developing. Emergency department teams must quickly... Read more
New Autoantibody Test Targets Pre-Symptomatic Type 1 Diabetes Screening
Type 1 diabetes is often first recognized only after substantial beta-cell destruction, sometimes presenting as diabetic ketoacidosis. Population-scale screening could identify children at elevated risk... Read more
Microbiology
view channel
One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens
Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more
FDA Clears Rapid Phenotypic Antimicrobial Susceptibility System for Positive Blood Cultures
Bloodstream infections require prompt treatment, but antimicrobial susceptibility results often lag behind a positive blood culture. Conventional testing can take another 24 to 48 hours after a culture... Read more
New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment
Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more
Pathology
view channel
New AI Model Maps Where Glioblastoma Could Return After Surgery
Glioblastoma is the most common malignant brain tumor in adults and the most lethal, with median survival of about 17 months after diagnosis. Even after surgeons remove all visible tumor and patients receive... Read more
Multimodal AI Supports Prostate Cancer Risk Assessment Across Diverse Cohorts
Artera’s (Los Altos, CA, USA) multimodal artificial intelligence (MMAI) platform is being featured in five abstracts at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting.... Read more
Technology
view channel
New Automation Workflow Streamlines NGS Library Preparation for High-Volume Labs
Demand for next-generation sequencing (NGS) continues to rise as laboratories process growing sample volumes, yet library preparation remains labor-intensive and a frequent source of variability.... Read more
ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine
Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more
Industry
view channel
Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection
Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Mayo Clinic Laboratories and Pathology Asia Expand Genomic Testing Across Asia-Pacific
Mayo Clinic Laboratories and Pathology Asia Holdings (PAH), together with subsidiary LifeStrands Genomics, announced a strategic investment and collaboration focused on expanding access to advanced diagnostics... Read more
